+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced NonSmall-Cell Lung Cancer: An Individual Patient Data Meta-analysis



Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced NonSmall-Cell Lung Cancer: An Individual Patient Data Meta-analysis



Yearbook of Oncology 2008: 165-167




(PDF emailed within 0-6 h: $19.90)

Accession: 063654050

Download citation: RISBibTeXText

DOI: 10.1016/s1040-1741(08)79212-1


Related references

CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 24(18_suppl): 7011-7011, 2016

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute 99(11): 847-857, 2007

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. Journal of Clinical Oncology 30(14): 1692-1698, 2012

Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced NonSmall-Cell Lung Cancer. Yearbook of Oncology 2008: 183-184, 2008

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer. Medicine 94(27): E1072, 2015

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 83(2): 211-218, 2014

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet. Oncology 15(11): 1254-1262, 2015

First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?. Journal of Thoracic Oncology 9(11): E82, 2015

Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology 23(16_suppl): 7218-7218, 2016

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. Esmo Open 3(6): E000327-E000327, 2018

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57(3): 348-358, 2007

A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics 13(2): 198-203, 2018

Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer. Journal of Thoracic Oncology 2(1): 96, 2007

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer 113(2): 388-395, 2008

Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trials. Journal of Clinical Oncology 26(15_suppl): 8052-8052, 2016